As more oral formulations enter the pipeline, the future of GLP-1 therapy promises greater flexibility, better adherence, and improved outcomes for millions of people living with type 2 diabetes
pharmacovigilance experts are monitoring for adverse signals beyond clinical trials
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have increasingly been used to treat type 2 diabetes mellitus
History of pancreatitis Severe gastrointestinal disease Gallbladder disease or a history of cholelithiasis Pregnancy or breastfeeding Concomitant use of insulin or insulin secretagogues (e.g., sulphonylureas), which may increase hypoglycaemia risk Retatrutide, like other incretin-class medicines, may slow gastric emptying, which can affect the absorption of oral medicines taken at the same time
(5) In the management of diabetes (including newly diagnosed type 2 diabetes), insulin therapy should be initiated as early as possible if there is significant unexplained weight loss[1]
